{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:30:18Z","timestamp":1794475818010,"version":"4.9.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ygyno.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:54:31Z","timestamp":1778864071000},"page":"120-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part II"],"prefix":"10.1016","volume":"209","author":[{"given":"Renata","family":"Urban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaranta","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitfield","family":"Growdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ygyno.2026.05.006_bb0005","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.08.032","article-title":"Prospective Phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer","volume":"224","author":"Westin","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2021.01.029","article-title":"Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: results of a randomized clinical trial","volume":"161","author":"Janda","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.05.006_bb0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajog.2024.07.018","article-title":"Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis","volume":"231","author":"Suzuki","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.05.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2013.06.031","article-title":"Combined medroxyprogesterone acetate\/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer","volume":"209","author":"Kim","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0030","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e47","article-title":"Six months response rate of combined oral medroxyprogesterone\/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-oncology group study","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2021.01.001","article-title":"Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer","volume":"161","author":"Novikova","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum. Reprod. Open"},{"issue":"10","key":"10.1016\/j.ygyno.2026.05.006_bb0045","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.ygyno.2026.05.006_bb0050","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.fertnstert.2011.07.1100","article-title":"The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study","volume":"96","author":"Luke","year":"2011","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0055","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ygyno.2021.04.017","article-title":"Updates on conservative management of endometrial cancer in patients younger than 45 years","volume":"161","author":"Lucchini","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.05.006_bb0060","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/IGC.0000000000000493","article-title":"European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial Cancer patients","volume":"25","author":"Rodolakis","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2026.05.006_bb0065","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Van Gorp","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.006_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO-24-01887","article-title":"Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors","volume":"43","author":"Slomovitz","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2026.05.006_bb0075","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial Cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.05.006_bb0080","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.05.006_bb0090","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.006_bb0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"issue":"S5","key":"10.1016\/j.ygyno.2026.05.006_bb0100","article-title":"Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA\/rEC) in the overall and mismatch repair proficient (MMR\/MSS) populations and in histological and molecular subgroups: results from part 2 of the RUBY trial","volume":"9","author":"M","year":"2024","journal-title":"ESMO Open."},{"issue":"9","key":"10.1016\/j.ygyno.2026.05.006_bb0105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without Olaparib as first-line treatment for advanced endometrial Cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.05.006_bb0115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-line Lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, Phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2026.05.006_bb0120","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch. Pathol. Lab Med."},{"issue":"12","key":"10.1016\/j.ygyno.2026.05.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101948","article-title":"Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review","volume":"35","author":"Gee-Rodriguez","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: a systematic review","volume":"17","author":"Decruze","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2026.05.006_bb0140","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic oncology group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic oncology group study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1471-0528.17331","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis","volume":"130","author":"van Weelden","year":"2023","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic oncology group study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101758","article-title":"Genomic alterations, molecularly targeted therapy, and survival: a real-world endometrial cancer molecularly targeted therapy consortium cohort study","volume":"35","author":"Secord","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","article-title":"Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis","volume":"118","author":"Barlin","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.05.006_bb0170","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ijgc-2023-004533","article-title":"Major determinants of survival in recurrent endometrial cancer-the role of secondary cytoreductive surgery: a multicenter study","volume":"33","author":"Vargiu","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ygyno.2021.05.020","article-title":"Non-exenterative surgical management of recurrent endometrial carcinoma","volume":"162","author":"Moukarzel","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"Creutzberg","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0185","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic oncology group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"9717","key":"10.1016\/j.ygyno.2026.05.006_bb0190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0195","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0360-3016(03)00414-0","article-title":"Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy","volume":"56","author":"Jhingran","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.ygyno.2026.05.006_bb0200","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.brachy.2017.07.012","article-title":"American brachytherapy society recurrent carcinoma of the endometrium task force patterns of care and review of the literature","volume":"16","author":"Kamrava","year":"2017","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2014.08.038","article-title":"Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification","volume":"113","author":"Vargo","year":"2014","journal-title":"Radiother. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2026.05.006_bb0210","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1200\/JCO.23.01279","article-title":"Radiation therapy with or without cisplatin for local recurrences of endometrial Cancer: results from an NRG oncology\/GOG prospective randomized Multicenter clinical trial","volume":"42","author":"Klopp","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2018.12.022","article-title":"Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer","volume":"152","author":"Ling","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.brachy.2021.12.010","article-title":"Clinical outcomes and dosimetric predictors of toxicity for re-irradiation of vaginal recurrence of endometrial cancer","volume":"21","author":"Lee","year":"2022","journal-title":"Brachytherapy"},{"issue":"4","key":"10.1016\/j.ygyno.2026.05.006_bb0225","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/IGC.0000000000000678","article-title":"Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients","volume":"26","author":"Schmidt","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2016.10.018","article-title":"Survival after pelvic exenteration for uterine malignancy: a National Cancer Data Base study","volume":"143","author":"Seagle","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/gyno.1999.5536","article-title":"Pelvic exenteration for recurrent endometrial cancer","volume":"75","author":"Barakat","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0240","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/IGC.0000000000000002","article-title":"Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients","volume":"24","author":"Chiantera","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2015.07.096","article-title":"Management of nodal recurrences of endometrial cancer with IMRT","volume":"139","author":"Ho","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2023.04.025","volume":"117","author":"Macchia","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.006_bb0255","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/ijgc-2023-004435","article-title":"Prognostic factors in patients with endometrial cancer with isolated lymphatic recurrence","volume":"33","author":"Capasso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 12","key":"10.1016\/j.ygyno.2026.05.006_bb0260","article-title":"Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors","volume":"9","author":"Anile","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0265","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ygyno.2020.10.001","article-title":"Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers","volume":"159","author":"Reshko","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.006_bb0275","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0295","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of letrozole and Abemaciclib in Estrogen receptor-positive recurrent endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.05.006_bb0300","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.05.006_bb0305","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0310","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.22.01021","article-title":"A phase Ib\/II study of Lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111\/KEYNOTE-146): long-term efficacy and safety update","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0315","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.006_bb0320","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines(R) insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"16","key":"10.1016\/j.ygyno.2026.05.006_bb0325","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0330","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.006_bb0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.01.025","article-title":"Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced\/recurrent endometrial cancer: an NRG oncology study","volume":"161","author":"Leslie","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.006_bb0340","article-title":"Adjuvant chemotherapy for advanced endometrial cancer","volume":"2014","author":"Galaal","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.ygyno.2026.05.006_bb0345","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic oncology group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.ygyno.2026.05.006_bb0350","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral Selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial Cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0355","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2012.04.013","article-title":"Cardiovascular disease is the leading cause of death among endometrial cancer patients","volume":"126","author":"Ward","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.006_bb0360","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ygyno.2012.03.042","article-title":"Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial","volume":"125","author":"von Gruenigen","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0365","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.006_bb0370","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000001447","article-title":"Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy","volume":"27","author":"Harris","year":"2020","journal-title":"Menopause"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:57Z","timestamp":1794473997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":74,"alternative-id":["S0090825826019803"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part II","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}